Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Besunyen Holdings Co. Ltd. ( (HK:0926) ) has issued an announcement.
Besunyen Holdings Co. Ltd. announced a significant fair value loss of approximately RMB16.3 million on its investment in ERX Pharmaceuticals Inc., a clinical-stage biopharmaceutical company. This loss is attributed to a shift in the U.S. capital market environment, where funding has moved towards technology sectors, affecting traditional drug development financing. Despite this, Besunyen’s liquidity remains strong, and the company plans to participate in a capital increase to maintain its stake in ERX, which aligns with its strategic interests in weight-loss therapies. The board believes this move will help restore ERX’s value and support its long-term growth, while preserving strategic partnerships and access to shared technology.
The most recent analyst rating on (HK:0926) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Besunyen Holdings Co. Ltd. stock, see the HK:0926 Stock Forecast page.
More about Besunyen Holdings Co. Ltd.
Besunyen Holdings Co. Ltd. operates in the health and wellness industry, primarily focusing on the development and sale of therapeutic teas and weight management products. The company is engaged in the discovery and clinical development of innovative drugs, particularly targeting obesity and related metabolic diseases.
Average Trading Volume: 12,883
Technical Sentiment Signal: Hold
Current Market Cap: HK$207.3M
See more insights into 0926 stock on TipRanks’ Stock Analysis page.